Hony Media Group Overview
Hony Media Group is a Hong Kong-listed, Cayman-incorporated micro-cap whose name has repeatedly lagged its business. Despite carrying "Media" in its name, essentially 100% of continuing revenue now comes from Echartnow (醫智諾), a Suzhou-based digitised-operations and compliant-marketing service provider to Chinese pharmaceutical companies (449 pharma clients and ~90,000 verified physicians). The entertainment franchise survives mainly as a 30.77% equity-accounted stake in South Korean drama producer HB Entertainment. In January 2026 the group sold its loss-making Meerkat Health pharma-wholesale platform for HK$1. Since June 2026 it has undergone a governance reset — Hony Capital's Zhao John Huan resigned as chairman, Tencent exited its stake, and long-time controlling figure Yuen Hoi Po returned as CEO — and pivoted toward a robotics operations platform (AIROBO) for China's property-management sector, backed by a 70%-owned JV. The company is loss-making, thinly capitalised and dependent on equity raises.
Company's own description (FY2025 Annual Report and 2026 Interim)
In its FY2025 Annual Report the Group described itself as principally engaged in three operating segments: (i) digitised operation services in the healthcare industry (Echartnow); (ii) a smart healthcare services platform (Meerkat Health); and (iii) entertainment and media. Following the January 2026 disposal of Meerkat Health, the 2026 interim results describe two continuing segments — Echartnow and Entertainment & Media — with Meerkat Health presented as a discontinued operation. The chairman's statement in the FY2025 AR framed the corporate vision around "AI + content", positioning the group to build a global platform for high-quality content creation, while Echartnow was described as "China's leading digital operations service provider for the pharmaceutical industry." From August 2026 the company added a third line — robotics platform operations via AIROBO (HK) Limited — and proposed renaming itself after that business.
Business model and revenue model
Echartnow (≈100% of continuing revenue, H1 2026). Echartnow earns information-technology service fees, consulting service fees and promotion service fees from pharmaceutical companies. Its revenue base is digitised marketing services: market research and site visits; execution of academic conferences, multidisciplinary-team (MDT) meetings and expert lectures (including live streaming and video editing); production and promotion of medical science-popularisation content (advertorials, short video, live broadcast); private- and public-domain precision promotion; and "doctor IP" brand-building for physicians. Higher-value services now include medical research support, real-world study (RWS) design, compliance-control tooling and AI-enabled patient-screening. The model is project/service-fee based (not subscription), with significant pass-through marketing cost (FY2025 gross margin 34.3%).
Entertainment & Media. No consolidated revenue in H1 2026 (FY2025: HK$0.23M). Economic exposure is via equity-accounted share of results of HB Entertainment (production of Korean TV dramas and films, and artist management).
Robotics platform operations (AIROBO, from Aug 2026). A hardware-agnostic "unified robotics operations platform" (AIROBO OS / AIROBO Platform 1.0) that connects multi-brand delivery, cleaning, inspection and security robots to property-management systems, elevators and access control. Revenue model not yet disclosed; co-build/co-operate agreements with property managers (5-year Longfor agreement; 3-year Greentown agreement) suggest platform/operations service fees. No revenue from this line had been reported as at 30 June 2026.
Discontinued: Meerkat Health. Originally a consumer smart-health platform (vaccines, health check-ups, private-domain e-commerce), it was pared back in 2024 to pharmaceutical wholesale only and sold on 30 January 2026.
Revenue mix by model (analyst characterisation, FY2025)
| Revenue model | Share of FY2025 revenue (%) | Basis |
|---|---|---|
| Services (Echartnow digitised operations) | 82.8 | HK$472.0M / HK$570.1M |
| Product trading (Meerkat pharma wholesale, now discontinued) | 17.2 | HK$97.9M / HK$570.1M |
| Licensing / IP products (Entertainment & Media) | 0.04 | HK$0.23M / HK$570.1M |
| Subscription | 0 | None disclosed |
Value-chain position, customers and end-markets
Echartnow sits between pharmaceutical manufacturers (buyers) and physicians/patients (audience), functioning as an outsourced, compliance-wrapped digital commercial-operations vendor — analogous to a digital contract sales/marketing organisation. Customers are Chinese pharma companies; top-100 Chinese pharma accounted for 61% of Echartnow revenue in FY2025 (59% in FY2024). Named clients include Yiling Pharmaceutical, Qilu Pharmaceutical, CSPC Pharmaceutical Group, Jemincare and Innovent Biologics. Customer concentration is high: one customer ("Customer B") generated HK$92.7M, ~42% of H1 2026 revenue.
Independent characterisation
Hony Media is best understood as a restructuring micro-cap shell with one operating asset (Echartnow) and a newly grafted growth narrative (robotics). Corporate identity has shifted five times in roughly a decade (health/wellness → Huayi Tencent entertainment → internet healthcare → Hony "AI + culture" → AIROBO robotics). Each pivot has coincided with a change in sponsor. The 2026 sequence — Hony Capital chairman exits (June), Tencent sells out (August), robotics JV and name change announced within days, stock rises ~51% intraday on 7 August — is characteristic of narrative-driven re-rating in Hong Kong small caps. Echartnow, by contrast, is a real business: it turned to a segment profit (HK$3.3M) in H1 2026 after two years of cost restructuring, though on shrinking revenue.
Strategy
Stated strategy themes
"AI + content" (FY2025 AR, Chairman's Statement, March 2026): build a global platform for creating and producing high-quality content; candidate tracks include AI micro-dramas, AI comic-dramas, AI movies and content globalisation. The AR cited global micro-drama in-app purchase revenue of nearly US$2.8bn in 2025. Status: effectively shelved — the 2026 interim says management maintains a prudent attitude to Entertainment & Media other than holding the HB stake, and the Hony Capital chairman behind this vision resigned in June 2026.
- Echartnow — "rooted in digital operations, winged by AI application scenarios": focus on Top-20 strategic clients with full-product-line access; replicate AI scenarios (chronic disease management, tumour follow-up); insurance collaborations on RWD; export the Shaanxi regional platform model; expand RWS and medical-data services ("Wei Jian Zhi Yan"); increase high-value project share; exit low value-added basic promotion.
Robotics platform operations (Aug 2026 onward): AIROBO as a neutral, multi-brand robot operations platform for property management; positioned as an "Android-like" OS layer between robot makers and buildings. Name change to AIROBO Platform Group signals this is now the core strategic narrative.
Initiatives in last 24 months
| Date | Initiative | Detail |
|---|---|---|
| Mar–Apr 2024 | Hony Capital partnership | HK$120M CB; Hony chairman installed; rename to Hony Media Group |
| 2,024 | Meerkat Health streamlining | Exited vaccines, check-ups, private e-commerce |
| H1 2025 | Echartnow restructuring | Headcount and fixed-cost reduction; group headcount 221 → 127 |
| 2,025 | Echartnow standards leadership | Led drafting of "Compliance Development Guidelines for Biopharmaceutical Digitized Operations"; Shanghai Biomedical Digitized Operation Standard Innovation Consortium |
| Dec 2025 | 10:1 share consolidation | Restores tradeable price |
| Jan 2026 | Meerkat Health disposal | HK$1 consideration |
| Jan–Mar 2026 | CB maturity extension | To 21 Apr 2028 |
| May–Jul 2026 | Equity placements | HK$110M gross at HK$0.40; July proceeds earmarked for Echartnow AI platform and R&D |
| Aug 2026 | AIROBO JV and Platform 1.0 | 70/30 JV; Chengdu entity; property-manager agreements |
| Aug–Sep 2026 | Ecosystem building | Co-founder of China Robot Industry Development Alliance; co-hosted robotics forum at Global Unicorn Summit (HK); CAS joint lab |
| Sep 2026 | Name change approved | AIROBO Platform Group Limited |
ESG commitments: water-conservation targets integrated into ESG management; TCFD-style four-pillar climate disclosure; no quantified emissions-reduction target disclosed. Cost programmes: ongoing AI-tool adoption to cut admin costs (admin −46% YoY in H1 2026). Medium-term financial targets/guidance: none disclosed. Management expected Echartnow to "gradually recover and resume growth in 2026" (FY2025 AR) — H1 2026 revenue was still −9%, but segment profit turned positive.
Products & Services
Echartnow (醫智諾) — Digitised operation services in healthcare
| Offering | Description / capabilities | Target customer | Year / status | Pricing model |
|---|---|---|---|---|
| Echartnow platform (WeChat mini-app origin) | Online ecosystem of ~90,000 real-name-verified physicians (end-2025, +48.9% YoY), covering paediatrics, oncology, cardiovascular etc. | Pharma marketing & medical affairs | Launched 2021 | Not disclosed (service/promotion fees) |
| Digitised marketing services | Market research, site visits, campaign decision support | Pharma brand teams | Core since 2021 | Project fees |
| Academic conference execution | Conference systems, MDT meetings, expert lectures, live streaming, video editing | Pharma medical/marketing | Core | Project fees |
| Medical science popularisation | Advertorials, short video, live broadcasts for physician-led health education | Pharma; physicians | Core | Promotion fees |
| Precision promotion | Private- and public-domain distribution of content (text, audio, video) | Pharma | Core | Promotion fees |
| Doctor IP incubation | Building physician personal brands; professional articles and videos | Pharma; KOL physicians | Expanding 2025 | — |
| High-value customised compliance marketing solutions | End-to-end compliance monitoring across business process; 36% of FY2025 Echartnow revenue, >50% in Q4 2025 | Top-tier & innovative pharma (e.g., Innovent) | Scaled 2025 | Customised fees |
| Medical research support & Real-World Study (RWS) design | Study design, data support | Innovative drug companies | Expanding 2025–26 | — |
| "Intelligent Screening for Patient Recruitment: AI Intelligent Screening Platform" | AI patient-screening for trial recruitment; listed on Suzhou AI Application Scenario Open List | Pharma R&D | 2,025 | — |
| "Pharmaceutical Marketing Compliance and Precision Empowerment Platform" | AI-enabled compliance control and precision marketing; on Suzhou AI list | Pharma commercial/compliance | 2,025 | — |
| "Comprehensive Medical Digital Empowerment Platform" (Shaanxi) | Designation by Shaanxi Provincial Data and Government Services Bureau; regional medical-data platform model | Local governments; pharma | 2,025 | — |
| "Wei Jian Zhi Yan" (衛健智研) RWD pilot | Real-world-data application pilot converting medical data "resources to assets" | Pharma, hospitals, clinical experts | Launched H1 2026 | — |
| Medical Data + AI Professional Committee (Xi'an Data Industry Association) | Echartnow serves as chairman unit | Industry ecosystem | H1 2026 | — |
| Specialised pharmacy / e-prescription system | Electronic prescriptions and online payment | Pharmacies, patients | Disclosed in ESG report | — |
| Planned: "AI + chronic disease management", "AI + tumour follow-up" | Roll-out to key customers nationwide | Pharma | Planned (FY2025 AR) | — |
| Planned: insurance collaborations | Efficacy evaluation & health management using RWD | Medical/commercial insurers | Planned | — |
Certifications: GB/T 19001-2016 / ISO 9001:2015 quality management (FY2025 ESG Report).
AIROBO — Robotics platform operations (from Aug 2026)
| Offering | Description / capabilities | Target customer | Year / status | Pricing |
|---|---|---|---|---|
| AIROBO OS / AIROBO Robotics Operations Management Platform 1.0 | Hardware-agnostic unified access for heterogeneous robots; unified data model; spatial-semantic building model; task orchestration; integration with elevators, access control, property systems; dozens of mainstream robot models adapted | Property-management companies | Officially launched 28 Aug 2026; deployed in Greentown Services projects | — |
| Longfor Property Robot Operations Platform | Co-built and co-operated platform; pilots at Huabei Yuhujing and Chengdu Xichen Yuanzhu (inspection & delivery robots) | Longfor Property Services | 5-year agreement, 17 Aug 2026 | — |
| Greentown property robotics platform | Co-built platform | Greentown Service (2869.HK) | 3-year agreement, Aug 2026 | — |
| Robot service agreement | Robot services | A-Living (3319.HK) | Sep 2026 | — |
| Robotics Operations Project Laboratory | Joint lab | Institute of Mechanics, Chinese Academy of Sciences | Sep 2026 | — |
Entertainment & Media (via HB Entertainment, 30.77% associate)
| Title / asset | Type | Year | Performance (Nielsen nationwide) |
|---|---|---|---|
| "Recipe for Love" (KBS 2TV) | Weekend TV drama | Jan 2026 | Average 14.5%, peak 18.0% (2026 Interim) |
| "Motel California" (MBC) | TV drama | Jan 2025 | Average 4.3%, peak 6.0% (FY2025 AR) |
| "Sky Castle" | TV drama | Back catalogue | — |
| "Partners for Justice" series | TV drama | Back catalogue | — |
| "My Love from the Star" | TV drama | Back catalogue | — |
| "Beautiful Love, Wonderful Life" | TV drama | 2,019 | Topped national ratings (FY2019) |
| Artist management roster | Lee Sung-min, Kim Yun-seok, Joo Sang-wook; Japanese actor Machida Keita | Ongoing | — |
| Historic film investments | 2015 film investment programme (~HK$369M); "Moonfall" (2022) | Legacy | — |
Discontinued
Meerkat Health (獴哥健康): smart health services platform; vaccines, health check-ups and private e-commerce exited in 2024; pharma wholesale until sale on 30 Jan 2026.
- Beijing Bayhood No.
Deep Sea Health stake (21.88%): held for sale; RMB23.2M disposal agreed.
Financial Narrative
Income statement
Notes: Operating loss is derived as gross profit + other income/gains − marketing & selling − R&D − administrative expenses (FY2025: 163.0 + 3.9 − 156.8 − 10.4 − 51.5). FY2022 loss before tax shown on restated basis (−317.0 as originally reported). EBITDA: not disclosed by the company; aggregator MarketInOut shows TTM EBITDA of approximately −HK$55.6M (Aug 2026). Revenue CAGR FY2021–FY2025: +15.2% (from a low base); FY2022–FY2025 (restated): −28.9% p.a.
Commentary. The five-year arc is a boom-and-bust in internet-healthcare revenue. Revenue jumped five-fold in FY2022 as Meerkat Health's trading revenue and Echartnow scaled, then contracted for three consecutive years. The FY2023 decline was Meerkat-driven (strategy change away from low-margin trading) while Echartnow grew 56%. FY2024 marked Echartnow's first decline (−8%) as pharma budgets tightened under China's anti-corruption campaign. FY2025 was the inflection: more than 60% of leading pharma companies suspended or cut non-core digital-marketing budgets in H1 2025, and Echartnow revenue halved — yet losses narrowed sharply because selling expense fell 56% and admin 27% after restructuring. Losses have never turned to profit in the period; cumulative net losses FY2021–FY2025 total about HK$837M against a market cap now under HK$800M.
Half-year trend (latest available)
Notes: H1 2025 revenue restated to continuing basis (Meerkat excluded). H1 2024 EPS is pre-consolidation; H1 2025/H1 2026 EPS reflect the 10:1 consolidation. H1 2026 loss benefited from a HK$11.1M one-off gain on CB modification, HK$5.5M gain on Meerkat disposal and HK$4.9M government AI subsidies; excluding these the adjusted continuing loss was HK$17.6M.
Balance sheet
The company's own gearing deducts HK$48.65M of deposits pledged against other borrowings. FY2025 equity attributable shows a minor inconsistency between the balance sheet (HK$89.1M) and statement of changes in equity (HK$89.2M).
30 June 2026 snapshot: total assets HK$357.8M; cash HK$60.3M (HK$28.2M held in RMB in the PRC); bank and other borrowings HK$103.0M (of which HK$58.1M interest-free other borrowings); CB HK$54.4M (now non-current, due 21 Apr 2028) plus HK$9.5M accrued interest; total equity HK$59.6M; equity attributable HK$123.6M; net current assets HK$31.6M; current ratio 1.20; gearing 0.93x. July 2026 placings added a further HK$65M gross.
Cash flow
The group burns roughly HK$45–55M of operating cash per year on current run-rates and has relied on equity placements (HK$110M gross raised May–July 2026) and borrowings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Echartnow revenue (HKD Mn) | 606.2 | 943.9 | 869.6 | 472.0 |
Meerkat Health revenue (HKD Mn) | 824.2 | 399.4 | 145.9 | 97.9 |
Entertainment and Media revenue (HKD Mn) | 151.0 | 0.7 | 3.1 | 0.2 |
Total revenue continuing basis (HKD Mn) | 1,581.4 | 1,344.0 | 1,018.5 | 570.1 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Echartnow revenue growth YoY (%) | — | 55.7 | -7.9 | -45.7 |
Meerkat Health revenue growth YoY (%) | — | -51.5 | -63.5 | -32.9 |
Echartnow share of revenue (%) | 38.3 | 70.2 | 85.4 | 82.8 |
Meerkat Health share of revenue (%) | 52.1 | 29.7 | 14.3 | 17.2 |
Entertainment and Media share of revenue (%) | 9.5 | 0.1 | 0.3 | 0.04 |
Results by Segment and Segment Margins & Growth (%)
| Segment metric (HKD Mn unless %) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Echartnow gross profit (HKD Mn) | — | — | 336.7 | 161.9 |
Echartnow gross margin (%) | — | — | 38.7 | 34.3 |
Echartnow segment result (HKD Mn) | — | — | -30.8 | -12.8 |
Meerkat Health gross profit (HKD Mn) | — | — | 19.1 | 1.1 |
Meerkat Health segment result (HKD Mn) | — | — | -6.9 | -3.8 |
Entertainment and Media gross profit (HKD Mn) | 1.1 | 0.7 | 3.1 | 0.03 |
Entertainment and Media segment result (HKD Mn) | -122.9 | 3.6 | -85.7 | -2.8 |
Total segment result (HKD Mn) | — | — | -123.3 | -19.4 |
Revenue by Segment and Segment Margins & Growth (%)
| Segment metric (HKD Mn unless %) | H1 2025 | H1 2026 |
|---|---|---|
Echartnow revenue (HKD Mn) | 241.1 | 220.1 |
Echartnow gross margin (%) | 33.1 | 35.0 |
Echartnow segment result (HKD Mn) | -11.9 | 3.3 |
Entertainment and Media revenue (HKD Mn) | 0.2 | 0.0 |
Entertainment and Media segment result (HKD Mn) | 1.0 | 0.8 |
Meerkat Health revenue discontinued (HKD Mn) | 61.1 | 0.1 |
Meerkat Health result discontinued (HKD Mn) | -2.0 | -0.3 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue as originally reported (HKD Mn) | 323.8 | 1,692.1 | 1,344.0 | 1,018.5 | 570.1 |
Revenue continuing ops restated (HKD Mn) | 323.8 | 1,581.4 | 1,344.0 | 1,018.5 | 570.1 |
Revenue growth YoY restated basis (%) | — | — | -15.0 | -24.2 | -44.0 |
Cost of sales (HKD Mn) | — | — | — | 659.6 | 407.1 |
Gross profit (HKD Mn) | — | — | — | 358.9 | 163.0 |
Gross margin (%) | — | — | — | 35.2 | 28.6 |
Marketing and selling expenses (HKD Mn) | — | — | — | 352.9 | 156.8 |
R&D expenses (HKD Mn) | — | — | — | 17.3 | 10.4 |
Administrative expenses (HKD Mn) | — | — | — | 70.4 | 51.5 |
Operating loss derived (HKD Mn) | — | — | — | -71.3 | -51.8 |
Operating margin derived (%) | — | — | — | -7.0 | -9.1 |
Net finance costs (HKD Mn) | — | — | — | -17.6 | -19.1 |
Share of associate results (HKD Mn) | -4.9 | -4.8 | -1.6 | -6.8 | -3.3 |
Impairment of associate (HKD Mn) | — | — | — | -76.1 | 0.0 |
Loss before taxation (HKD Mn) | -141.8 | -318.1 | -119.6 | — | — |
Net loss for the year (HKD Mn) | -141.4 | -316.6 | -125.4 | -177.2 | -76.3 |
Net loss attributable to owners (HKD Mn) | — | — | — | -163.5 | -66.7 |
Adjusted non-HKFRS loss (HKD Mn) | — | — | — | -103.2 | -73.1 |
Net margin (%) | -43.7 | -20.0 | -9.3 | -17.4 | -13.4 |
Dividend per share (HKD) | — | — | — | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | H1 2023 | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Revenue as reported (HKD Mn) | 687.7 | 489.4 | 241.3 | 220.1 |
Gross profit continuing (HKD Mn) | — | — | 79.8 | 77.0 |
Loss for the period (HKD Mn) | -57.4 | -46.2 | -42.6 | -5.0 |
Loss attributable to owners (HKD Mn) | -43.8 | -41.0 | -35.0 | -5.2 |
Basic loss per share (HK cents) | — | -0.30 | -2.57 | -0.35 |
Balance Sheet and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (HKD Mn) | — | 360.5 |
Cash and cash equivalents (HKD Mn) | 34.5 | 23.9 |
Bank and other borrowings (HKD Mn) | 75.1 | 83.9 |
Convertible bonds liability (HKD Mn) | 115.9 | 59.5 |
Lease liabilities (HKD Mn) | — | 4.6 |
Net debt derived (HKD Mn) | 156.5 | 124.1 |
Long-term financial liabilities Yitang (HKD Mn) | — | 56.1 |
Total liabilities (HKD Mn) | — | 332.6 |
Total equity (HKD Mn) | 23.7 | 27.9 |
Equity attributable to owners (HKD Mn) | 103.3 | 89.2 |
Non-controlling interests (HKD Mn) | -79.6 | -61.3 |
Goodwill (HKD Mn) | — | 27.2 |
Intangible assets (HKD Mn) | — | 0.3 |
Interest in associate HB Entertainment (HKD Mn) | — | 100.6 |
Net current assets (HKD Mn) | 2.8 | -84.1 |
Current ratio (x) | 1.02 | 0.69 |
Gearing company definition (x) | 4.9 | 2.8 |
Cash Flow
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Operating cash flow (HKD Mn) | -28.2 | -24.7 |
Capex PP&E and intangibles (HKD Mn) | -0.2 | -0.1 |
Free cash flow derived (HKD Mn) | -28.4 | -24.8 |
Proceeds from share issuance (HKD Mn) | 0.0 | 45.0 |
Net borrowing inflow (HKD Mn) | 11.9 | 15.7 |
Dividends paid (HKD Mn) | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 |
Financial Analysis
| Ratio | Value | Basis |
|---|---|---|
ROE (attributable) | approx. −69% | −66.7 / avg(103.3, 89.2), derived |
ROE (aggregator) | −86.0% | MarketInOut, Aug 2026 |
ROA (aggregator) | −17.2% | MarketInOut |
ROIC (aggregator) | −17.6% | MarketInOut |
Current ratio | 0.69 (FY2025); 1.20 (30 Jun 2026) | Filings |
Debt/equity (aggregator) | 1.66 | MarketInOut |
Net debt / EBITDA | Not meaningful (negative EBITDA) | — |
Interest coverage | Not meaningful (negative EBIT) | — |
Asset turnover | approx. 1.6x | 570.1 / 360.5, derived |
Altman Z-score (aggregator) | −6.79 | MarketInOut |
Piotroski F-score (aggregator) | 3/9 | MarketInOut |
Revenue by geography (HKD Mn)
| Revenue by geography (HKD Mn) | H1 2025 | H1 2026 |
|---|---|---|
PRC revenue (HKD Mn) | 241.3 | 220.1 |
Hong Kong revenue (HKD Mn) | 0.0 | 0.0 |
South Korea revenue (HKD Mn) | 0.0 | 0.0 |
Non-current assets by geography (HKD Mn)
| Non-current assets by geography (HKD Mn) | FY2025 | H1 2026 |
|---|---|---|
PRC non-current assets (HKD Mn) | 42.1 | 42.5 |
Hong Kong non-current assets (HKD Mn) | 1.7 | 1.1 |
South Korea non-current assets (HKD Mn) | 100.6 | 99.8 |
Share Price
| Metric | 2026-07-28 | 2026-08-03 | 2026-09-28 | 2026-10-09 |
|---|---|---|---|---|
Share price close (HKD) | 0.39 | 0.52 | 0.41 | 0.45 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | ~HK$791M | 1,757.15M shares |
Enterprise value | ~HK$895M |
|
EV / Sales (TTM continuing ~HK$451M) | ~2.0x | Derived |
P/E | n/m (loss) | — |
EV/EBITDA | n/m (negative) | Aggregator −13.1x |
P/B (equity attributable HK$123.6M) | ~6.4x | Derived |
Analyst coverage | 0 analysts | Simply Wall St |
Analyst Conclusions
Management guidance: No numerical guidance. Management expects Echartnow to stabilise and grow its high-value share, expand RWS/medical-data services and deepen Top-20 client relationships; robotics is to be scaled through property-manager platform agreements. No consensus estimates exist (zero analyst coverage).
Bull case
-
Echartnow has crossed into segment profitability (H1 2026) with improving gross margin; revenue stabilisation from a lower, higher-quality base could produce group breakeven in 2027.
-
AIROBO has signed blue-chip property managers (Longfor, Greentown, A-Living, Central China, Excellence) within weeks; a platform model with recurring fees could command a technology multiple.
-
Balance sheet repaired: CB pushed to 2028, cash raised HK$110M in 2026, current ratio >1.
Bear case
-
Revenue has shrunk ~64% from the FY2022 peak; one client is ~42% of revenue; the core market faces regulatory budget compression.
-
Robotics is pre-revenue, relies on a newly founded partner, and press reports describe the platform as early-stage; the rename resembles prior narrative pivots that did not create value.
-
Sponsor exits (Hony, Tencent), a vacant chair, pledged core assets and serial dilution at HK$0.40 suggest limited institutional support; 2028 CB and Yitang obligations loom.
Catalysts / monitorables (next 12 months)
-
Effective date of AIROBO Platform Group name and new short name.
-
First disclosed AIROBO revenue, contract values and robot fleet metrics (FY2026 results, ~March 2027).
-
Appointment of a new chairman and any board refresh.
-
Echartnow H2 2026 revenue trend and Customer B concentration.
-
Further placements/dilution; any asset injection related to AIROBO's controller.
-
Progress (or not) toward a Suzhou Yizhinuo IPO versus the Yitang repurchase clause.
-
HB Entertainment pipeline and potential monetisation of the 30.77% stake.
Analyst verdict. Hony Media Group is not a media company and, on current evidence, not yet a robotics company. It is a small, cash-consuming PRC pharma-marketing services business — Echartnow — wrapped in a Hong Kong listed shell that has been repeatedly re-purposed by successive sponsors. Echartnow deserves credit: after a brutal FY2025 in which revenue halved under China's pharma compliance crackdown, management cut costs aggressively, lifted the share of high-value compliance work above half of revenue, and delivered a small segment profit in H1 2026. That is real operating progress, and the policy direction toward traceable, digital commercial operations is a genuine structural tailwind. However, the business remains sub-scale, highly concentrated in one customer, and still shrinking at the top line.
The 2026 governance sequence is the decisive analytical fact. Within eight weeks, Hony Capital's chairman resigned, Tencent sold out, control reverted to long-standing shareholder-director Yuen Hoi Po, a robotics JV was formed with a months-old partner, and a rename to AIROBO Platform Group was proposed and approved. Equity was raised at HK$0.40 while the stock subsequently traded higher on the robotics narrative. Investors should treat AIROBO as an option with unquantified economics: there is no disclosed revenue, contract value, unit economics or patent portfolio, and the platform's capability claims largely originate from the partner and press releases.
Valuation at roughly 2x EV/Sales and over 6x book embeds substantial robotics optionality on top of a marginally profitable services segment. Absent disclosed robotics revenue and a credible independent chairman, risk-reward skews negative for fundamental investors, with high volatility suited only to speculative positioning. The FY2026 annual results will be the first real test of whether the AIROBO narrative converts into reportable numbers. Stance: Speculative / High Risk — monitor, do not underwrite on narrative alone.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background | Age |
|---|---|---|---|---|
YUEN Hoi Po (袁海波) | Executive Director & CEO (from 18 Jun 2026); chairs Executive and Corporate Governance Committees; member Remuneration & Nomination Committees; interim chair functions | Long-standing director (aggregator shows ~15 years); CEO pre-Apr 2024, President Apr 2024–Jun 2026 | Bachelor's, Heilongjiang University; trade, real estate, tourism and services since 1990; INED of Minsheng International (938.HK) Nov 2018–Jan 2025; sole shareholder/director of substantial shareholder Smart Concept Enterprise Limited | 63 |
CHENG Wu (程武) | Executive Director (CEO Apr 2024–Jun 2026; earlier Vice-Chairman) | ED since c.2016 Tencent era | Joined Tencent Nov 2009; Group VP; chairman Tencent Animation & Comic and Tencent Literature; CEO Tencent Pictures; former CEO China Literature; NED Maoyan Entertainment (Jun 2020–Nov 2022) | b.1975 |
YUEN Kin | INED; chairs Audit and Remuneration Committees |
| — | — |
WANG Song Song | INED; Audit, Remuneration, Nomination member | — | — | — |
PAN Min | INED; chairs Nomination Committee; Audit member | — | — | — |
Chairman | Vacant since 18 Jun 2026 | — | Company searching for candidate | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
24 Apr 2024 | Zhao John Huan appointed NED & Chairman; Cheng Wu appointed CEO; Yuen Hoi Po to President | Linked to Hony Capital's HK$120M CB investment |
3 Nov 2025 | INED Chu Yuguo resigned | Committee reshuffle |
18 Jun 2026 | Zhao John Huan resigned (other work arrangements); Cheng Wu resigned as CEO (personal work arrangements); Yuen Hoi Po redesignated CEO | Chair vacant; CG Code C.2.1 deviation disclosed |
Major Shareholders
| Holder | Shares (M) | Approx. % | Basis / caveat |
|---|---|---|---|
Yuen Hoi Po (personal 45.9M + Smart Concept Enterprise 193.8M) | 239.7 | 13.6 | 18 Jun 2026 announcement; % derived |
Tencent Holdings (historical controlling shareholder) | Sold ~202M (~11.5%) on 7 Aug 2026 | Reported as exit | etnet; residual not confirmed |
Hony Capital vehicle (CB holder) | 59.8 (conversion shares) + 60.5 potential on conversion | 3.4 (6.6 fully converted) | Interim Note 28; % derived |
Liu Dongwei & Wang Xueting (May 2026 subscribers) | 112.5 combined (split n/d) | 6.4 | Interim Note 27 |
July 2026 independent subscribers (several) | 162.5 combined | 9.2 | Interim Note 32 |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors | Positioning vs. Hony |
|---|---|---|
Pharma digital marketing / physician platforms (Echartnow) | MedLive Technology (2192.HK); DXY (丁香園, private); Medlinker (private); Yidu Tech (2158.HK, RWD/data); Ping An Health (1833.HK); JD Health (6618.HK) and Alibaba Health (0241.HK) in adjacent pharma services; traditional CSOs | Echartnow is sub-scale versus MedLive/DXY in physician reach (~90k verified doctors) but differentiates on compliance-wrapped execution and regional government platforms |
Robotics operations in property management (AIROBO) | Onewo (2602.HK) robotics services; Country Garden Services (6098.HK) robotics; UBTech (9880.HK); robot OEMs with own fleet software — Pudu, Keenon, Gausium, Youibot (03231.HK, also a partner) | AIROBO is hardware-agnostic and early-stage; OEMs and large property managers can build in-house |
Content / Korean & Chinese drama (E&M) | Studio Dragon (KOSDAQ: 253450); SLL; CJ ENM; Huanxi Media (1003.HK); Maoyan (1896.HK); Alibaba Pictures (1060.HK); Huayi Brothers (300027.SZ) | Hony has only a minority associate stake; no scale |
Competitor Detail
| Metric | Hony Media FY2025 |
|---|---|
Revenue | HK$570.1M |
Revenue growth | −44% |
Gross margin | 28.6% |
R&D intensity | 1.8% |
Recent Developments
--



